Edition:
United States

Accuray Inc (ARAY.O)

ARAY.O on Nasdaq

4.45USD
21 Jul 2017
Change (% chg)

-- (--)
Prev Close
$4.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
729,285
52-wk High
$6.39
52-wk Low
$3.85

Latest Key Developments (Source: Significant Developments)

Accuray sees Q4 revenue about $111.5 million to $112 million
Monday, 17 Jul 2017 04:05pm EDT 

July 17 (Reuters) - Accuray Inc :Accuray announces preliminary fourth quarter and fiscal year 2017 results.Sees Q4 revenue about $111.5 million to $112 million.Sees FY revenue about $382.8 million to $383.3 million.Accuray Inc says ending backlog as of June 30 is expected to be approximately $453 million.Accuray expects to finish fiscal year with approximately $108 million in cash, cash equivalents & investments.Accuray Inc says gross product orders for Q4 are expected to be approximately $86 million.Preliminary revenue and product order results for Q4 and fiscal year 2017 expected to be in line with guidance provided in april.Q4 revenue view $111.1 million -- Thomson Reuters I/B/E/S.FY2017 revenue view $382.5 million -- Thomson Reuters I/B/E/S.  Full Article

Neuro Spinal Hospital in Dubai to buy Accuray Cyberknife and Radixact Systems
Tuesday, 11 Jul 2017 07:30am EDT 

July 11 (Reuters) - Accuray Inc :Accuray Inc - ‍deal was entered into backlog during Accuray's fourth fiscal quarter which ended June 30, 2017​.Accuray - ‍agreement with Neuro Spinal Hospital in Dubai for acquisition of one Cyberknife M6 System and one Radixact System​.  Full Article

Accuray Inc signs new revolving loan agreement
Thursday, 15 Jun 2017 07:30am EDT 

June 15 (Reuters) - Accuray Inc ::Accuray enters into new revolving loan agreement.Closed a new $52 million senior secured revolving loan facility with Midcap Financial Trust.  Full Article

Accuray reports prelim data from phase I trial of breast cancer cure treated with Cyberknife System
Tuesday, 2 May 2017 07:30am EDT 

May 2 (Reuters) - Accuray Inc :Prelim data from phase I trial evaluating adjuvant stereotactic partial breast irradiation in early stage breast cancer patients treated with Cyberknife System.S-PBI provides more convenient treatment option than hypofractionated whole-breast irradiation with no compromise in tolerability or short-term efficacy.  Full Article

Accuray Q3 loss per share $0.06
Thursday, 27 Apr 2017 04:01pm EDT 

April 27 (Reuters) - Accuray Inc :Q3 loss per share $0.06.Q3 revenue $97.3 million.Accuray Inc - gross product orders totaled $83.8 million for 2017 fiscal Q3 compared to $56.4 million for prior fiscal year period.Accuray Inc qtrly ending product backlog was $450.0 million, approximately 21 percent higher than backlog at end of prior fiscal year Q3.Accuray Inc - 2017 outlook for gross orders growth of approximately five percent is reaffirmed.Accuray Inc - revenue for fiscal year is now expected to range between $380.0 million and $390.0 million.Accuray Inc - 2017 adjusted EBITDA is now expected to range between $22.0 million and $26.0 million.FY 2017 revenue view $407.2 million -- Thomson Reuters I/B/E/S.  Full Article

Accuray on March 10, co entered into an amendment to financing agreement dated as of Jan. 11, 2016
Friday, 10 Mar 2017 05:50pm EST 

Accuray Inc : On March 10, co entered into an amendment to financing agreement dated as of January 11, 2016 - sec filing . Accuray Inc - second amendment requires company to obtain a letter of credit in face amount of $12.5 million for benefit of administrative agent . Accuray Inc - second amendment makes certain related amendments to debt and lien covenants and financial ratio definitions .Accuray - second amendment increased interest rate margins under financing agreement by 0.50% until certain specified conditions are met.  Full Article

Accuray posts Q2 loss per share $0.11
Tuesday, 31 Jan 2017 04:01pm EST 

Accuray Inc : Q2 ending product backlog was $426.2 million, approximately 16 percent higher . Q2 loss per share $0.11 . Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S . Qtrly total revenue was $87.5 million compared to $108.9 million in prior fiscal year Q2 . Reaffirming guidance originally provided on August 17, 2016 for fiscal year 2017 for all metrics except operating expenses . FY2017 earnings per share view $-0.19, revenue view $409.4 million -- Thomson Reuters I/B/E/S .Q2 revenue view $90.4 million -- Thomson Reuters I/B/E/S.  Full Article

Accuray reports Q4 loss per share $0.09
Wednesday, 17 Aug 2016 04:01pm EDT 

Accuray Inc : Accuray reports fourth quarter and fiscal 2016 financial results . Q4 loss per share $0.09 . Q4 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S . Q4 revenue $95 million versus i/b/e/s view $99 million . Sees FY 2017 revenue $410 million to $420 million . Backlog increased 8 percent year-over-year to $405.9 million in quarter . Sees fy 2017 adjusted ebitda $32.0 million to $38.0 million . FY2017 revenue view $431.8 million -- Thomson Reuters I/B/E/S . Qtrly gross orders increased 12 percent over prior year period to $95.4 million . Sees FY 2017 backlog and gross orders growth of approximately 5 percent .Approximately 55 percent of revenue and 60 percent of gross orders are anticipated in second half of fiscal year in fy 2017.  Full Article

Accuray CE marks its radixact system
Tuesday, 9 Aug 2016 06:30am EDT 

Accuray Inc : CE marked its radixact treatment delivery system, Accuray precision treatment planning system and IDMS data management system . Platform will now be available in certain markets in European Union (EU) .Have shipped first commercially released radixact system to a site in U.S. and expect first eu shipment during fiscal Q1 2017.  Full Article

Accuray retires remaining 3.75 percent convertible debt
Tuesday, 2 Aug 2016 06:30am EDT 

Accuray Inc : Retires remaining 3.75 percent convertible debt . Says 2016 notes were settled on August 1 for $37.3 million, which included $36.6 million in principal and $0.7 million in accrued interest .Says settled remaining principal amount and accrued interest thereon of 3.75 percent convertible senior notes.  Full Article

BRIEF-Neuro Spinal Hospital in Dubai to buy Accuray Cyberknife and Radixact Systems

* Accuray Inc - ‍deal was entered into backlog during Accuray's fourth fiscal quarter which ended June 30, 2017​